Interaction of Chloramphenicol Cationic Peptide Analogues with the Ribosome

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Structural Biology

Background:

• Chloramphenicol is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the ribosome.
• Development of novel antibiotics is crucial due to increasing antimicrobial resistance.
• Exploring modifications of existing antibiotics can yield compounds with improved efficacy and binding characteristics.

Purpose of the Study:

• To design and synthesize novel tripeptide analogues of chloramphenicol.
• To evaluate the binding affinity of these analogues to bacterial ribosomes.
• To assess the antibacterial activity and ribosomal binding mechanism of promising candidates.

Main Methods:

• Virtual screening using molecular docking to predict binding affinity to bacterial ribosomes.
• Chemical synthesis of selected chloramphenicol analogues, including chloramphenicol amine (CAM) derivatives with proline-rich antimicrobial peptide fragments.
• Experimental validation of ribosome binding using fluorescent erythromycin analogue displacement assays.
• In vitro protein biosynthesis inhibition assays and chemical probing to determine mechanism of action.

Main Results:

• Molecular docking identified tripeptide analogues with high affinity to bacterial ribosomes.
• Synthesized analogues, particularly those incorporating proline-rich peptide fragments, demonstrated enhanced binding to Escherichia coli ribosomes compared to chloramphenicol.
• A correlation was observed between calculated and experimentally determined ligand efficiencies.
• The RAW-CAM analogue exhibited protein biosynthesis inhibition activity comparable to chloramphenicol.
• Chemical probing confirmed that the RAW-CAM analogue binds to the nascent peptide exit tunnel similarly to chloramphenicol.

Conclusions:

• Novel peptide analogues of chloramphenicol can effectively bind to bacterial ribosomes.
• Certain designed analogues exhibit significantly greater affinity for bacterial ribosomes than the parent compound.
• The RAW-CAM analogue represents a promising lead compound with chloramphenicol-like activity and a similar binding mode.
• These findings support the development of new antimicrobial agents based on modified chloramphenicol structures.